Cytotoxins

Subscribe to Selected New Research on Cytotoxins

1932 relevant articles (148 outcomes, 183 trials/studies) found for this Bio-Agent

Description: Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS.

Also Known As:

Cytolysins; Cytotoxic Agents

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Experts

1.	Coley, Helen M: 3 articles (03/2008 - 10/2006)
2.	Miller, Duane D: 3 articles (03/2007 - 04/2005)
3.	Dalton, James T: 3 articles (03/2007 - 04/2005)
4.	Gududuru, Veeresa: 3 articles (03/2007 - 04/2005)
5.	Agarwal, Rajesh: 2 articles (09/2007 - 02/2004)
6.	Reynolds, C Patrick: 2 articles (07/2007 - 06/2007)
7.	Keshelava, Nino: 2 articles (07/2007 - 06/2007)
8.	Shotton, Christine F: 2 articles (01/2007 - 10/2006)
9.	Thomas, Hilary: 2 articles (01/2007 - 10/2006)
10.	González, Mercedes: 2 articles (08/2006 - 05/2006)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2003 - "Clearly, many of today's cytotoxic agents have been shown to be effective in-vitro and in animal model systems; however, few have proved efficacious in dramatically improving survival outcomes in adult cancer. " 10/15/2000 - "These studies suggest that fusion constructs targeting the HER2/neu surface domain and containing TNF are more effective cytotoxic agents in vitro than native TNF and may be effective against tumor cells expressing intermediate, but not high, levels of HER2/neu." 01/15/2004 - "Successful therapy requires that the cytotoxic agents reach the tumor cells. " 06/01/1998 - "More recently, the identification of a wide range of genes and corresponding protein products that are altered in various human cancers has revealed new molecular targets for cancer therapy that may provide improved selectivity for tumor cells over traditional cytotoxic agents. " 07/01/1997 - "To date, four major strategies have been adopted: 1) modifying the tumor cell itself either by "repairing" one or more genetic defect associated with the malignant process, introducing a gene that will trigger an anti-tumor immune response, or delivering a pro-drug metabolizing enzyme that will render the tumor sensitive to the corresponding cytotoxic agent; 2) modifying the immune response to the tumor by altering the specificity or effector function of immune system cells; 3) decreasing the sensitivity of normal host tissue by delivering cytotoxic drug resistance genes to marrow precursor cells and thereby increasing the therapeutic index of cytotoxic agents; and 4) marking normal and malignant hemopoietic cells in order to more closely monitor the efficacy of conventional therapies. " Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 02/01/2005 - "Although breast cancer is most often treated with conventional cytotoxic agents it has proved difficult to induce apoptosis in breast cancer cells, but improved clinical responses may be obtained by identifying therapies that are particularly effective in activating apoptosis. " 01/01/2005 - "Although breast cancer is most often treated with conventional cytotoxic agents it has proved difficult to induce apoptosis in breast cancer cells and, consequently, improved clinical responses may be obtained by identifying therapies that are particularly effective in activating apoptosis. " 01/01/2001 - "Despite the common clinical use of numerous active cytotoxic agents for breast cancer therapy, and the combinations that are derived from them, the median survival for patients with metastatic breast cancer has not been dramatically improved over the past two decades. " 08/01/1999 - "This review was performed to determine the efficacy of commonly used cytotoxic agents in the management of anthracycline-resistant breast cancer, using a stringent and uniform definition of drug resistance. " 11/01/1997 - "Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models." Order ALL the reference details at left...
3.	Carcinoma (Carcinomatosis) 05/01/2004 - "SUMMARY: Better knowledge of nasopharyngeal carcinoma pathogenesis and biology, management of patients in highly specialized oncologic units, and careful selection of cytotoxic agents along with multimodality integrated therapeutic programs will likely yield to improved survival, particularly for patients with locally advanced nasopharyngeal carcinoma." 01/01/1997 - "Previously, we have assessed the efficacy of different cytotoxic agents on the viability of SW620 human colonic carcinoma cells in vitro. " 01/01/2001 - "Early clinical trials are being designed to address these concerns; however, the clinical impact of non-cytotoxic agents in epithelial ovarian carcinoma patients must await the completion of randomized evaluations in combination with standard chemotherapeutic regimens." 07/01/2000 - "This study was conducted to evaluate the effectiveness of angiogenesis inhibitor 6-O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470. AGM-1470) in the treatment of nasopharyngeal carcinoma (NPC) alone and in combination with cytotoxic agents. " 10/01/2006 - "This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment." Order ALL the reference details at left...
4.	Vasculitis (Vasculitides) 03/01/2006 - "This latter strategy might also be effective against HIV-associated vasculitis and, unlike cytotoxic agents, does not jeopardize the outcome of HIV-infected patients. " 12/01/1980 - "The cytotoxic agents appear to hold some promise in the therapy of vasculitis, but problems with their use have by no means been solved. " 12/01/2005 - "CONCLUSIONS: MMF is a reasonable option in the treatment of non-life-threatening recurrent or resistant vasculitis and may obviate the immediate need for recurrent use of cytotoxic agents." 12/01/1986 - "Correlation of LCT with the activity of vasculitis implies that these cytotoxins may have a pathogenetic role and perhaps may serve as a marker for disease activity." 04/01/2007 - "This strategy is also effective for human immunodeficiency virus-associated vasculitis and, unlike cytotoxic agents, does not jeopardize the outcome of acquired immunodeficiency syndrome. " Order ALL the reference details at left...
5.	Neoplasm Metastasis (Metastasis) 12/01/1988 - "The high incidence of distant metastases underscores the need for earlier diagnosis and effective systemic cytotoxic agents if survival is to be significantly improved in these patients." 07/01/1998 - "Efficacy of cytotoxic agents for the prevention of laparoscopic port-site metastases." 07/01/1998 - "This study investigated in an experimental model the influence of cytotoxic agents (administered intraperitoneally or intramuscularly) on the development of port-site metastases following laparoscopic surgery. " 01/01/2008 - "CONCLUSIONS: This retrospective analysis demonstrated that patients with liver metastases only had high objective response rates and encouraging results for median survival obtained with currently available cytotoxic agents." 06/01/2004 - "Irrigation of port sites with cytotoxic agents has been suggested to prevent port site metastases. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Adrenal Cortex Hormones (Corticosteroids)
2.	Monoclonal Antibodies
3.	gemcitabine
4.	Doxorubicin (Adriamycin)
5.	Paclitaxel (Taxol)
6.	gefitinib (Iressa)
7.	Epidermal Growth Factor Receptor (EGF Receptor)
8.	Azathioprine (Imuran)
9.	Steroids
10.	Carbon Monoxide

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Plasmapheresis
4.	Plasma Exchange
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>